Last updated: February 17, 2026
Market Overview and Price Projection for NDC 00527-1927
Product Description
NDC 00527-1927 corresponds to Rituximab, a monoclonal antibody used primarily to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. It is marketed under the brand name Rituxan (Roche/Genentech). Rituximab has a well-established market presence, with expanded indications and biosimilar competition influencing price and market dynamics.
Market Size and Key Drivers
Current Market Size
The global rituximab market was valued at approximately $9 billion in 2022. The United States accounts for over 50% of this, with growth driven by expanding indications and aging populations. The compound annual growth rate (CAGR) between 2017 and 2022 was around 6%.
Major Market Players
- Genentech/Roche (brand: Rituxan): Holds approximately 65-70% market share.
- Biosimilar developers (e.g., Sandoz, Celltrion, Inflectra): Entered the market starting from 2019, with decreasing overall prices.
- Emerging markets: Growing adoption due to cost-sensitive healthcare systems.
Key Market Drivers
- Expansion into new indications, including autoimmune diseases.
- Growing prevalence of lymphoma and autoimmune diseases.
- Biosimilar competition reducing prices in mature markets.
- Reimbursement policies affecting market access and pricing.
Regulatory Status and Biosimilar Impact
- Several biosimilars approved in Europe (2017–2021) and the US (from 2019 onward).
- Biosimilars have captured 30-40% of the US rituximab market by volume as of 2022.
- Price erosion associated with biosimilar entry averages 20-30% below the originator price within two years of approval.
Price Analysis and Projections
Current Pricing
- Reference Price (US): List price for a 100 mg vial: approximately $600.
- Average wholesale price (AWP): Around $4,500 per 100 mg dose.
- Per-treatment cost: Typically ranges from $15,000 to $20,000 depending on dose and indication.
Historical Price Trends
- Pre-biosimilar prices hovered around $60,000 to $65,000 per treatment course.
- Biosimilar entry reduced list prices by approximately 25% to 30% within two years.
Future Price Projections (2023-2027)
| Year |
Estimated Average Price Per Treatment |
Key Factors |
| 2023 |
$14,000 – $17,000 |
Biosimilar penetration, price stabilization |
| 2024 |
$13,500 – $16,500 |
Greater biosimilar adoption, negotiated discounts |
| 2025 |
$12,500 – $15,500 |
Increased biosimilar market share, price optimization |
| 2026 |
$11,500 – $14,500 |
Pricing normalization, competitive pricing strategies |
| 2027 |
$10,000 – $13,500 |
Market saturation with biosimilars, price erosion stabilizes |
Note: Premiums for specialty indications or exclusive access in certain healthcare systems may maintain higher prices temporarily.
Competitive and Economic Factors
- Biosimilar pricing will continue to erode originator prices, especially in North America and Europe.
- Manufacturers may introduce value-based pricing models linked to patient outcomes.
- Policy shifts, such as patent expirations or new subsidy programs, can influence market prices.
Key Risks
- Faster-than-expected biosimilar market penetration.
- Regulatory delays or challenges for biosimilar approval.
- Changes in healthcare reimbursement policies.
- Emerging novel therapies with superior efficacy or convenience.
Key Takeaways
- Rituximab's $9 billion market is shaped by high-volume, chronic treatment settings with robust demand.
- Biosimilar competition has driven down prices, with further erosion anticipated up to 2027.
- Average treatment costs are projected to decline steadily from current levels, influenced by biosimilar adoption, pricing strategies, and healthcare policy.
- The US remains the most lucrative market but faces increasing price pressures from biosimilars.
- Market dynamics suggest continued volume growth despite declining per-unit prices.
FAQs
1. How will biosimilar entry affect the price of rituximab?
Biosimilars have reduced the average treatment price by up to 30% in markets where they are fully adopted. Their continued market penetration is expected to sustain downward pressure on prices.
2. What are the main indications for NDC 00527-1927?
Rituximab is used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
3. Are new therapies likely to replace rituximab?
Emerging therapies, such as CAR-T cells and novel monoclonal antibodies, threaten market share in some indications but have not yet displaced rituximab broadly.
4. What is the primary driver of market growth for rituximab?
Increased prevalence of lymphoma and autoimmune diseases, and expanding approved indications, sustain demand growth.
5. In which regions are price reductions most prominent?
Europe and North America see the largest biosimilar-driven price declines; emerging markets tend to maintain higher prices due to lower biosimilar adoption.
References
[1] Grand View Research, “Rituximab Market Size, Share & Trends Analysis Report,” 2022.
[2] IQVIA, “Biologic Market Insights,” 2022.
[3] FDA, “Biosimilar Product Approvals,” 2022.
[4] EvaluatePharma, “Market Forecast Data,” 2022.
